Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study

Table 3 Univariate and multivariate analysis of prognostic factors in patients (OS)

Parameters	Univariate					Multivariate
Parameters	Median (months)	95% CI	HR	95% CI	p-value	HR	95% CI	p-value
Age
≤ 65	15.8	10.3–21.4	0.91	1.59–0.52	0.744
> 65	8.2	1.1–15.3
Sex
Male	13.3	3.8–22.9	0.77	0.43–1.38	0.375
Female	11.6	5.3–17.8
Smoking status
Smoker	22.3	16.7–27.9	0.62	0.28–1.39	0.244
Never smoker	11.3	5.5–17.0
Performance status, PS
PS 2	15.8	8.8–22.9	0.86	0.49–1.53	0.615
PS ¾	8.4	2.3–14.6
Mutation					0.52
L858R	11.7	7.7–15.6	0.67	0.27–1.65	0.382
19del	18.1	9.1–27.1	0.59	0.24–1.46	0.253
Uncommon	3.5	0.5–6.6
Starting dose
40 mg	17.5	11.6–23.4	0.59	0.34–1.05	0.073	0.93	0.51–1.72	0.827
30 mg	8.1	2.6–13.5
Metastatic sites
Lung
Yes	10.1	4.9–15.2	1.26	0.72–2.19	0.422
No	15.8	11.0–20.7
Liver
Yes	3.1	0.0–18.5	1.85	0.97–3.52	0.061	2.15	1.1–4.18	0.024
No	13.8	8.9–18.6
Brain
Yes	17.5	11.6–23.4	0.94	0.54–1.64	0.838
No	10.8	6.7–15.0
Bone
Yes	18.1	11.5–24.8	0.66	0.38–1.15	0.147
No	8.4	1.7–15.2
Pleura
Yes	8.1	0.0–17.8	1.59	0.90–2.81	0.112
No	15.5	8.2–22.8
Adrenal gland
Yes	10.1	0.0–29.7	1.28	0.46–3.55	0.641
No	12.9	8.4–17.3
Distant lymphadenopathy
Yes	15.5	0.0–39.8	1.11	0.47–2.62	0.804
No	11.7	8.1–15.2
Dose reduction/interruption
Yes	20.3	15.8–24.8	0.65	0.37–1.15	0.138
No	8.1	0.1–16.1
Discontinuation, AE-related
Yes	17.5	0.0–38.6	0.59	0.23–1.48	0.261
No	11.7	8.2–15.2
Clinical tumor response					< 0.001			< 0.001
CR/PR	18.1	13.6–22.7	0.15	0.08–0.3	< 0.001	0.14	0.05–0.42	< 0.001
SD	20.3	0.0–43.5	0.14	0.05–0.39	< 0.001	0.14	0.07–0.30	< 0.001
PD/NA	1.5	0.0–3.1
BMI			1.01	0.93–1.10	0.867
BSA			0.33	0.02–5.99	0.451

CR complete response, PR partial response, SD stable disease, PD progressive disease, NA not assessed, AE adverse events, BMI body mass index, BSA body surface area, HR hazard ratio, CI confidence interval, OS overall survival

ISSN: 1471-2407